The HIV community will soon be seeing twice-yearly data from the PURPOSE 1 clinical trial. Rena Capa Building Preliminary results have shown it to be 100%...
The HIV-1 capsid inhibitor lenacapavir, administered as a twice-yearly injection, was 100% effective in preventing HIV infection in women at high risk of infection, according to...
Recent Comments